These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31872348)

  • 1. Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models.
    Wang L; Hu C; Wang A; Chen C; Wu J; Jiang Z; Zou F; Yu K; Wu H; Liu J; Wang W; Wang Z; Wang B; Qi Z; Liu Q; Wang W; Li L; Ge J; Liu J; Liu Q
    Invest New Drugs; 2020 Oct; 38(5):1272-1281. PubMed ID: 31872348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
    Rahaman MH; Yu Y; Zhong L; Adams J; Lam F; Li P; Noll B; Milne R; Peng J; Wang S
    Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK9 inhibitors in acute myeloid leukemia.
    Boffo S; Damato A; Alfano L; Giordano A
    J Exp Clin Cancer Res; 2018 Feb; 37(1):36. PubMed ID: 29471852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
    Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
    Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
    Lee DJ; Zeidner JF
    Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
    Thomas D; Powell JA; Vergez F; Segal DH; Nguyen NY; Baker A; Teh TC; Barry EF; Sarry JE; Lee EM; Nero TL; Jabbour AM; Pomilio G; Green BD; Manenti S; Glaser SP; Parker MW; Lopez AF; Ekert PG; Lock RB; Huang DC; Nilsson SK; Récher C; Wei AH; Guthridge MA
    Blood; 2013 Aug; 122(5):738-48. PubMed ID: 23775716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and optimization of selective and potent CDK9 inhibitors with flavonoid scaffold for the treatment of acute myeloid leukemia.
    Wu T; Yu B; Gong W; Zhang J; Yu S; Tian Y; Zhao T; Li Z; Wang J; Bian J
    Eur J Med Chem; 2023 Nov; 259():115711. PubMed ID: 37572539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.
    Han X; Song N; Saidahmatov A; Wang P; Wang Y; Hu X; Kan W; Zhu W; Gao L; Zeng M; Wang Y; Li C; Li J; Liu H; Zhou Y; Wang J
    J Med Chem; 2021 Oct; 64(19):14647-14663. PubMed ID: 34477384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
    Lücking U; Kosemund D; Böhnke N; Lienau P; Siemeister G; Denner K; Bohlmann R; Briem H; Terebesi I; Bömer U; Schäfer M; Ince S; Mumberg D; Scholz A; Izumi R; Hwang S; von Nussbaum F
    J Med Chem; 2021 Aug; 64(15):11651-11674. PubMed ID: 34264057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
    Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
    Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.
    Fiskus W; Manshouri T; Birdwell C; Mill CP; Masarova L; Bose P; Kadia TM; Daver N; DiNardo CD; Borthakur G; Khoury JD; Verstovsek S; Bhalla KN
    Blood Cancer J; 2022 Jan; 12(1):23. PubMed ID: 35102145
    [No Abstract]   [Full Text] [Related]  

  • 13. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
    Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
    Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
    Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
    Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.
    Minzel W; Venkatachalam A; Fink A; Hung E; Brachya G; Burstain I; Shaham M; Rivlin A; Omer I; Zinger A; Elias S; Winter E; Erdman PE; Sullivan RW; Fung L; Mercurio F; Li D; Vacca J; Kaushansky N; Shlush L; Oren M; Levine R; Pikarsky E; Snir-Alkalay I; Ben-Neriah Y
    Cell; 2018 Sep; 175(1):171-185.e25. PubMed ID: 30146162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
    Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
    Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
    Lyle L; Daver N
    Am J Manag Care; 2018 Aug; 24(16 Suppl):S356-S365. PubMed ID: 30132679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development.
    Liu Y; Xu Z; Hu L; Xia L; Li Q; Zhou W; Chen Y; Li W; Jiang W; Zhu X; Gao X; Xia Y; Zhu Z; Chen S; Ding CZ
    Bioorg Med Chem Lett; 2024 Nov; 112():129941. PubMed ID: 39222890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
    Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
    PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
    Beauchamp EM; Abedin SM; Radecki SG; Fischietti M; Arslan AD; Blyth GT; Yang A; Lantz C; Nelson A; Goo YA; Akpan I; Eklund EA; Frankfurt O; Fish EN; Thomas PM; Altman JK; Platanias LC
    Blood; 2019 Mar; 133(11):1171-1185. PubMed ID: 30587525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.